ResearchImpact of Pre-treatment Testosterone Levels on Severity of Adverse Effects in Men on Androgen Deprivation Therapy for Prostate Cancer
ResearchAccelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
ResearchFORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
ResearchSystemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
ResearchImmune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
ResearchHSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer
Aug 6, 2026Original ArticlePerioperative Apalutamide in High-Risk Localized Prostate CancerWritten by 1 Roon author & 22 others Via The New England Journal of Medicine
ResearchSystemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
ResearchAssociation between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer
ResearchLong-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer
ResearchOutcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
ResearchSystemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
ResearchSystemic treatment options for metastatic castration resistant prostate cancer: A living systematic review
ResearchMuscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant
ResearchBCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways